Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study

INTRODUCTION: Brexpiprazole is a novel antipsychotic drug. It exerts antagonistic activity at the serotonin 5HT2A, 5HT2B, 5HT7 and noradrenaline alpha 1b/2c receptors; it also acts as partial agonist of serotonin 5HT1 and dopamine D2, D3 receptors. Brexpiprazole is approved for the treatment of schi...

Descripción completa

Detalles Bibliográficos
Autores principales: Civardi, S.C., Bassetti, N., Arienti, V., Besana, F., Politi, P., Brondino, N., Olivola, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567215/
http://dx.doi.org/10.1192/j.eurpsy.2022.881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567215/
http://dx.doi.org/10.1192/j.eurpsy.2022.881

Ejemplares similares